Analyst firms · Robert W. Baird · EW

Robert W. Baird EW price target and rating history

Edwards Lifesciences Corporation (EW) · Health Care

Robert W. Baird rates Edwards Lifesciences Corporation (EW) Outperform with a $116 price target, as of its latest action on Nov 5, 2026. It has published 3 rating actions on EW since July 2023, including 1 upgrade and 1 downgrade. Across 7 firms with a EW price target in the last 12 months, the median target is $110. Robert W. Baird's $116 is 5% above that.

Current rating
Outperform
Price target
$116
Median target, all firms
$110
Actions on EW
3

Robert W. Baird price target on EW

$116$93$70202420252026
Robert W. Baird price target on EW, each point a stated target, July 2023 to November 2026.

Every Robert W. Baird rating on EW

How other firms rate EW

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Robert W. BairdOutperform$116Nov 5, 2026
Truist SecuritiesBuy$113Nov 4, 2026
BarclaysOverweight$110Oct 7, 2026
UBSBuy$110Jul 28, 2026
Leerink PartnersOutperform$101Jul 24, 2026
Wolfe ResearchOutperform$92Apr 1, 2026
TD CowenBuy$97Jan 9, 2026

Questions about Robert W. Baird and EW

What is Robert W. Baird's price target for EW?
Robert W. Baird's latest stated price target for Edwards Lifesciences Corporation (EW) is $116, from its action on Nov 5, 2026.
What is Robert W. Baird's rating on EW?
Robert W. Baird rates EW Outperform, a bullish rating, as of Nov 5, 2026.
When did Robert W. Baird last change its view on EW?
On Nov 5, 2026, Robert W. Baird upgrades to Outperform from Neutral, price target $116.
How does Robert W. Baird's EW target compare with other analysts?
Across 7 firms with a EW price target in the last 12 months, the median target is $110. Robert W. Baird's $116 is 5% above that.

More EW rating histories

All Robert W. Baird ratingsEW news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.